Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Capital Markets Day

On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced the completed transfer of assets into its wholly owned, US-based...
Read more

Results from Oasmia Pharmaceutical’s phase III study will be presented at ASCO annual meeting in June

Oasmia Pharmaceutical AB announce that follow-up results from the completed phase III study with Apealea® for treatment of ovarian cancer will be presented at the 2018 ASCO Annual Meeting in Chicago....
Read more

Notification from Oasmia Pharmaceutical

Oasmia Pharmaceutical AB (publ) hereby notify that the Company, Arwidsro Investment and MGC Capital have agreed to extend the payment of the loan, which was communicated January 2nd  until...
Read more
To news archive